Biodesix (BDSX) Operating Income (2019 - 2026)

Biodesix has reported Operating Income for 8 years, with the latest figure at -$6.2 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Income rose 32.13% year-over-year to -$6.2 million; the trailing twelve-month figure through Mar 2026 stood at -$24.9 million (up 23.53% YoY), and the FY2025 full-year result was -$27.9 million, up 19.2% from the prior year.
• Operating Income for Q1 2026 stood at -$6.2 million, down from -$2.0 million in the prior quarter.
• The five-year high for Operating Income was -$2.0 million in Q4 2025, with the low at -$16.4 million in Q1 2023.
• Historically, Operating Income has averaged -$9.4 million across 5 years, with a median of -$9.1 million in 2025.
• Annual changes were most pronounced in 2022 — Operating Income tumbled 159.02% — and 2025, when it soared 70.42%.
• Biodesix's Operating Income stood at -$13.9 million in 2022, then surged by 50.54% to -$6.9 million in 2023, then climbed by 3.22% to -$6.6 million in 2024, then soared by 70.42% to -$2.0 million in 2025, then tumbled by 215.25% to -$6.2 million in 2026.
• The last three Operating Income figures came in at -$6.2 million (Q1 2026), -$2.0 million (Q4 2025), and -$7.1 million (Q3 2025), per Business Quant data.